WAVEMAN · COMPANY

AZN · Astrazeneca Plc

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

AZN

Name: ASTRAZENECA PLC (AZN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

ASTRAZENECA PLC

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000901832

CONGRESS · 3☆ WATCH

INSIDER NET · 180D

-$2.2M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

794

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$2.2M over 180 days

below 69% of Pharma & Biotech

CONGRESS

3 members bought in the last year

more than 89% of Pharma & Biotech

FUNDS

794 funds added or opened last quarter

more than 99% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

1.0 days to cover · settled 2026-07-31

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

794 funds added or opened positions in the latest 13F quarter, of 1,511 holders.

3 members of Congress reported buying it this year.

1 clinical trial was terminated, suspended or withdrawn in the last 90 days.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +2.5%

+2.5%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $2.2M sold by insiders over 180 days, 794 funds added last quarter, 3 Congress member(s) bought in 12 months. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ASTRAZENECA PLC insiders sold a net $2.2M of stock across 1 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Sharma Mani

See Remarks

SELL

2026-05-20

11,893.0

$2.2M

1 TRANSACTION ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Evelyn Partners Group Ltd

2,237,205.0 sh

$41.5B

INVESTOR AB

51,587,810.0 sh

$9.8B

VANGUARD CAPITAL MANAGEMENT LLC

45,386,190.0 sh

$8.5B

Capital International Investors

34,576,070.0 sh

$6.5B

NORGES BANK

33,864,172.0 sh

$6.3B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Parnassus Value Select ETF

$1.1M POSITION · AS OF 2026-03-31

6.1%

AlphaCentric Life Sciences and Healthcare Fund

$2.2M POSITION · AS OF 2026-03-31

5.6%

Janus Henderson Global Life Sciences Fund

$238.6M POSITION · AS OF 2026-03-31

4.6%

Invesco V.I. Health Care Fund

$6.5M POSITION · AS OF 2026-03-31

4.4%

CRAWFORD LARGE CAP DIVIDEND FUND

$2.5M POSITION · AS OF 2026-03-31

4.3%

Invesco Health Care Fund

$47.3M POSITION · AS OF 2026-04-30

4.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 1117 registered trials, 504 still enrolling or running — a status change here is dated weeks before the press release

249

Phase 1

56 ACTIVE

151

Phase 2

69 ACTIVE

255

Phase 3

172 ACTIVE

Phase 4

11 ACTIVE

Early Phase 1

0 ACTIVE

367

Not applicable

151 ACTIVE

Multi-phase

45 ACTIVE

What changed recently

Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability o

2026-09-05 · Completion moved 2026-12-02 → 2026-12-03

Phase 1

Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability o

2026-09-05 · Not Yet Recruiting → Recruiting

Phase 1

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients Wi

2026-09-04 · Completion moved 2025-11-28 → 2027-02-10

Phase 2

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

2026-09-04 · Completion moved 2027-08-07 → 2028-02-07

Phase 3

Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient S

2026-09-04 · Active Not Recruiting → Completed

—

CHARM Hepatocellular Carcinoma MEA Study

2026-09-04 · Not Yet Recruiting → Recruiting

—

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
GROSS PROFIT	$48.1B	$43.9B	$37.5B	$32.0B
NET INCOME	$10.2B	$7.0B	$6.0B	$3.3B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE